Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 120.38

-1.7%

2:04 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Elmer who started this subject	7/28/2004 1:02:27 AM
From: mopgcw	of 276

Illumina Notified of Patent Lawsuit 2004-07-27 21:29 (New York) SAN DIEGO--(BUSINESS WIRE)--July 27, 2004--Illumina, Inc. (Nasdaq:ILMN) has received notification that a lawsuit has been filed against the Company by Affymetrix Inc. alleging infringement of six Affymetrix patents. The patents were issued to Affymetrix between 1996 and 2003, and relate to various aspects of arrays, software and hardware. The Company believes it has meritorious defenses and plans to vigorously defend itself against these allegations. "It is disappointing that Affymetrix has chosen to attempt to compete in the courtroom rather than in the marketplace," stated Jay Flatley, Illumina President and CEO. "We believe our next-generation BeadArray-based products provide the highest combination of quality and price performance in the industry and are being well received in the marketplace," added Flatley. Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology -- now used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will correlate genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next